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INTRODUCTION
The introduction of combination antiretroviral 
therapy (cART) represented a medical break-
through in the treatment of Human Immu-
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Since the first acquired immunodeficiency syndrome cases were reported in 1981, more than 1.5 million people 
have been diagnosed with Human Immunodeficiency Virus-1 in Europe, including more than 136,000 new HIV 
cases in 2013. Recent epidemiological data estimate an incidence of 5-10 newly diagnosed HIV infections per 
100,000 population per year in Europe and an average prevalence of infection of 5.7 cases per 100,000 popu-
lation. In the absence of an effective curative strategy for HIV, optimization of prevention policies and clinical 
management of HIV positive patients is fundamental to reduce the impact of the HIV pandemic on public health. 
Clinical trials represent an essential tool for translating research findings into routine clinical practice. Careful 
evaluation and planning of clinical trials are therefore mandatory in order to provide relevant information to 
clinicians. The HEFFICON Project was conceived to investigate and pinpoint methodological issues and critical 
points that need to be addressed in future clinical studies to increase the translation of experimental results to 
the real life environment.
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nodeficiency Virus (HIV) infection, leading to 
effective suppression of viral replication and a 
dramatic increase in the life expectancy of HIV 
seropositive patients. Nevertheless, cART is not 
curative and patients need to take medications 
lifelong in order to control viral replication. 
From an epidemiological perspective, the in-
creased longevity of HIV patients drove the for-
mation of a more heterogeneous population of 
patients including individuals diagnosed at dif-
ferent stages of the disease and thus treated for 
different amounts of time. The heterogeneity of 
the HIV seropositive population and the wide 
range of clinical conditions deriving from HIV 
infection itself and HIV-associated co-morbid-
ities pose great challenges in the clinical man-
agement of HIV patients. From the translation-
al medicine perspective, these questions point 
to the need for clinical studies taking into ac-
count the specific characteristics of each group 
of patients. 
Taking advantage of the EPICO methodology, 
the next chapters will outline the state of the 
art in HIV clinical practice and investigate the 
research questions that remain to be answered 
in clinical studies in specific HIV settings.
1 - EARLY TREATMENT OF PATIENTS
Coordinator A. Lazzarin
Introduction 
From the etiopathogenetic point of view, HIV 
infection will become chronic in all cases. To-
day the therapeutic armamentarium of drug 
combinations available show 90% or better 
efficacy, therefore leaving no doubt over the 
principle that HIV infection must be treated 
promptly.
As a model of intervention, primary HIV in-
fection (PHI) provides some fundamental in-
formation, which will be analysed in detail in 
the following chapters as a real life example of 
when and whether there is an indication for 
early treatment.
First, however rapid the diagnosis may be in 
the natural history of serum conversion (Feibig 
1-4 status) (Fiebig et al., 2003), this cannot 
prevent the spread of the retrovirus out of the 
anatomical site of the primary focus of infec-
tion (Ananworanich et al., 2012; Whitney et al., 
2014). Only in some of the patients treated for a 
sufficiently long period (>5 years) does early di-
agnosis lead to the condition of “post-treatment 
élite controller” once antiretroviral treatment 
has been suspended (Saez-Cirion et al., 2013).
Clinical trials and observational studies have 
not yet reached a final conclusion on the di-
lemma of recommending treatment of pri-
mary HIV infection (PHI) and for how long. 
This highlights the limitations of clinical trial 
evidence: insufficient numbers of treated sub-
jects, non-homogenous treatments, and most of 
all, diversity in terms of levels of viremia, CD4 
count, and symptoms.
When infection is not identified at onset (i.e., 
in almost all cases) or in those subjects where 
treatment cannot be deferred (AIDS and/or 
late - presenters =+/-40%), the decision when to 
start combination ART (cART) can be deduced 
only from the evaluation of patient cohorts fol-
lowed during these years, to obtain consistent 
information on the risk of progression of the 
infection to full-blown disease based on the as-
sociation with biological criteria such as CD4 
and HIV-RNA (surrogate markers).
The associated progression risk factor usually 
considered, and still the most reliable, is the 
number of CD4/mm3, which led to the standard 
threshold of 350 CD4/mm3 for cART being rec-
ommended.
Since the rule of starting antiretroviral thera-
py <350 CD4/mm3 was established, the thresh-
old for early treatment naturally moved before 
to 500 CD4/mm3 and today to >500 CD4/mm3 
without restriction aiming at treating patients 
with low immune-deficiency (Lodi et al., 2011; 
Antinori et al., 2012). In this setting, it is much 
more difficult to gather information leading to 
a clear understanding and/or assessment of risk 
evolution in terms of morbidity and most of all, 
mortality (currently >1%). 
However, the 500 CD4/mm3 threshold is already 
considered in those cases where co-factors of 
progression are present (co-morbidity or ag-
ing).
The response to this question, and to whether 
there is the indication for treatment for all HIV 
positive subjects, could come from the START 
study (early versus deferred treatment in sub-
jects with >500 CD4/mm3), whose results are 
expected in at least two years from now. 
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In the meantime, the choice to make in stable 
chronic asymptomatic infection showing a fair-
ly good immune response is “personalized early 
treatment”. This is true in those patients prom-
ising good compliance in long-life therapy and 
who are not threatened by long-term treatment 
side-effects, selecting the best cost/benefit drug 
combination and therapeutic strategy.
Patients with PHI
G. Tambussi, A. Gori
Evidence. The availability of potent cART for 
people infected with HIV led to the reduction of 
both progression to AIDS- and HIV-associated 
morbidity and mortality. According to current 
consensus, initiation of therapy is best based 
on CD4 count rather than on viral load (Ster-
ling et al., 2001).
National and international guidelines provide 
different recommendations for starting treat-
ment. Over the past 10 years, the CD4 cell count 
threshold for ART initiation has risen steadily 
in parallel with the development of new ther-
apeutic strategies, new knowledge acquisition 
and new presentations of HIV disease. How-
ever, these different treatment approaches can 
be confusing for clinicians, patients and poli-
cy-makers when they are called to define the 
best time to initiate therapy. 
Optimizing the initiation of ART is clearly com-
plex and must therefore be balanced between 
individual and broader public health needs. In 
particular, intense scientific discussion still sur-
rounds the merits of initiating treatment during 
acute/primary HIV infection. Despite the lack 
of randomized clinical trials, arguments in fa-
vor of early treatment were largely fueled by the 
theoretical assumption that intervention at this 
stage of the disease may provide a unique op-
portunity to preserve the immune system deep-
ly affecting the entire course of the disease. 
Many concerns have been raised about ART 
initiation during PHI, the strongest including 
potential long-term toxicity, development of 
resistant virus strains and costs. However, re-
cent advances in antiretroviral therapy provid-
ed well-tolerated highly effective drugs which 
guarantee an excellent compliance, strongly re-
ducing the risk of resistance (Assoumou et al., 
2013). In addition, early treatment initiation 
improves survival, prevents viral reservoirs dif-
fusion (Yerly et al., 2000) and reduces the risk of 
HIV transmission (Cohen et al., 2011b). 
Others issues raised against early treatment of 
HIV infection are the increased ART exposure, 
for how long therapy should be prolonged or if, 
at this point, a suspension of therapy is indeed 
justified once this has been initiated. 
Regarding the first issue, given the increased 
survival of people living with HIV, the decision 
to start early treatment occurs in a relative-
ly narrow window of time in the life span of 
a person with HIV infection. A few extra years 
of therapy out of a total of 40 to 50 years on 
treatment for those living a near-normal life 
span represent, in our opinion, relatively minor 
differences in long-term exposure to treatment. 
Population. The decision to treat patients with 
acute HIV infection is based on facts and hy-
pothesis. However several shortcomings affect 
data on primary/early HIV infection treatment. 
Amongst others, it is difficult to identify per-
sons at early stages of HIV infection because 
of limitations in diagnostic techniques and the 
paucity of symptoms occurring during this par-
ticular phase of the HIV infection (Branson and 
Stekler 2012).
Despite the aid of useful algorithms (Fiebig et 
al., 2003), it is not always easy to differentiate 
PHI from an early infection. In this latter case, 
therapeutic intervention is likely to be initiated 
well after peak viremia, and extensive damage 
may already have been done.
Intervention. In the past year, 3 prospective, 
randomized, controlled studies (Fidler et al., 
2002; Grijsen et al., 2012; Hogan et al., 2012) 
have evaluated the potential benefits of antiret-
roviral treatment initiation during acute HIV-1 
infection.
These studies provide evidence that greater 
CD4 cell recovery is achieved with earlier initi-
ation of therapy during PHI, but the question of 
whether the relatively small clinical advantages 
of therapy outweigh the disadvantages of treat-
ment remains unanswered. 
On the other hand, these articles support the 
current Department of Health and Human Ser-
vices and International Antiviral Society-USA 
guidelines for resource-rich settings, which 
suggest ART for nearly everyone who is HIV-in-
fected, regardless of the stage of infection. 
Obviously, this recommendation is definitely 
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stronger to justify the decision to undertake the 
treatment of a primary infection.
More recently, data from the “Visconti” (Viro-
logical and Immunological Studies in Control-
lers after Treatment Interruption) trial, showed 
that some patients treated early during PHI 
have no signs of viral load rebounds follow-
ing termination of their treatment regimens 
(Saez-Cirion et al., 2013). This evidence may 
ultimately provide guidance to scientists pur-
suing a “functional” HIV cure, as long as treat-
ment starts early enough. 
Outcome. It is thus conceivable to think that 
treatment of PHI might provide additional ben-
efits (i.e. less damage to the immune system, 
in particular to the gut mucosal immunity, and 
reducing the extent of viral reservoirs (Chun et 
al., 2007). Finally, patients who receive diagno-
sis and adequate ART for enough time shortly 
after infection, may also have a better chance 
of responding to “functional cure” strategies, as 
suggested by the Visconti cohort.
While awaiting a “definitive” clinical study, it is 
ethical to consider early treatment, which can 
be defined as “plausible” based on our under-
standing of HIV biology, HIV pathogenesis, the 
availability of better drugs, the evidence from 
cohort studies, and the public health implica-
tions of viral load suppression and decreased 
HIV transmission.
Patients with high CD4 counts: 
early treatment as prevention
A. Castagna, E. Nicastri
Evidence. A recent survey of 1675 HIV clini-
cians from New York and Washington USA 
conducted from September 2010 and May 
2011 suggests that only half of them prescribe 
HAART to HIV patients with CD4 cell strata 
ranging from 350 to 500 CD4/mm3 and that in 
only 15% of cases is HAART started irrespective 
of CD4 cell value (Kurth et al., 2012). 
The evidence-based data on antiretroviral ther-
apy initiation based on CD4 cell count come 
from Cohorts and Randomized Controlled Tri-
als (RCT) with viro-immunological and clinical 
end points.
Data from patients with 350-500 CD4 cell/mm3 
are consistent in both Cohort and RCT trials 
with clinical and surrogate endpoints. Con-
versely, in patients with >500 CD4/mm3 there 
are no data at all from RCT, while in the NA-Ac-
cord there is statistically significant evidence 
of a better clinical performance, but very few 
cases are collected and appear to drive this 
conclusion. Finally, in case of HIV serodiscor-
dant couples (98% of them in monogamous 
heterosexual relationships) the HPTN 052 tri-
al showed strong evidence of benefit of early 
HAART initiation irrespective of CD4 cell count: 
96% reduction in HIV transmission (P <0.001) 
(Cohen et al., 2011b). Recently, confirming data 
on the clinical benefit of early treatment in the 
350-500 CD4/mm3 stratum were reported in the 
HPTN 052 trial (Grijsen et al., 2012).
Although anticipated (Attia et al., 2009), this 
finding has catalyzed enormous interest in how 
ART could not only benefit the single individu-
al, but also reduce the epidemic burden in the 
community 
Population. Recently, a supplement of the 
PLOS Medicine Journal was published on the 
topic of treatment as prevention. Mathematical 
models provide a framework to assemble data 
on the impact that different treatment programs 
can have on preventing HIV infections, and sev-
eral models of the epicenter of the worldwide 
epidemic, sub-Saharan Africa, have been used 
to investigate the potential impact of treatment 
on HIV incidence. In this collection, Eaton and 
coworkers et al. (Eaton et al., 2012) presented 
the results of a systematic model comparison 
exercise in which 12 of these models were used 
to simulate the same sets of interventions. The 
model results were relatively consistent for 
short-term (eight-year) projections of reduc-
tion in incidence associated with treatment (i.e. 
80% of individuals with<350 CD4/mm3); the 
models projected that the incidence rate would 
be reduced by 35%-54%, compared with what it 
would be in the absence of any ART. 
Intervention. In spite of inconsistencies be-
tween modeling assumptions and projects and 
real world situations, treatment as a preven-
tion strategy has already generated major re-
ductions in incidence in a few selected catego-
ries. The Option B+ approach of lifelong ART 
for all HIV-infected pregnant women, regard-
less of CD4 count, is an example of this poli-
cy.(Schouten et al., 2011; World Health Orga-
nization 2012b). The advantages of OptionB+ 
include a simplification of PMTCT program; 
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extended protection from MTCT in future preg-
nancies directly from conception; a prevention 
benefit against sexual transmission in serodis-
cordant couples; likely benefit to the woman’s 
health of earlier treatment and avoiding the 
risks of stopping and starting antiretrovirals; 
full integration between HIV center of treat-
ment and care and antenatal care centers; and 
a simple message to communities: once ART is 
started, it is taken for life. Still, there are im-
portant programmatic, operational and clinical 
challenges, including service organization and 
delivery of antiretrovirals, cost and sustainabil-
ity. But major limits in the preliminary reports 
from different African countries (Francesco 
Vairo, personal communication) on Option B+ 
are retention in care and the maintenance of 
optimal adherence to HAART. 
Outcome. It is reasonable to discuss the option 
of an earlier therapy in patients with chronic 
HIV infection with good immunology status to 
preserve immune system deterioration and to 
avoid AIDS- or non-AIDS-defining events. How-
ever, at this time no unequivocal definitive clin-
ical study claims that early treatment should be 
considered the standard of care. The WHO mod-
el of Option B+ in HIV-infected pregnant women 
could provide the long-term clinical and viro-im-
munological data from a clinical perspective to 
confirm the choice of an initial antiretroviral 
treatment irrespective of CD4 cell count.
2 - ADVANCED PATIENTS WITH 
INFECTIOUS COMORBIDITIES
Coordinator C.F. Perno
Introduction 
It is estimated that across Europe about one-
third of HIV-infected persons are unaware of 
their HIV status. One of the main consequences 
of this scarce knowledge of HIV status is a sig-
nificant level of late diagnosis and a robust rate 
of virus transmission (obviously longer and 
stronger, whenever the duration of the infection 
lasts over the years in conditions of good health 
and consequent normal life habits, such as sex-
ual activity) (Fisher 2008; Adler et al., 2009). 
HIV late-presenters can be defined as those pre-
senting with “advanced HIV disease”, that is a 
CD4 cell count <200 cells/mm3 or with and an 
AIDS defining condition (Thompson et al., 2012; 
World Health Organization 2013; Panel on An-
tiretroviral Guidelines for Adults and Adoles-
cents 2014b). Late presentation is dangerous in 
terms of individual and social health, and trans-
verse efforts in planning common strategies at 
European level have been extensively carried 
forward: recently, European guidelines have 
been developed for implementing HIV testing 
in adults in public healthcare settings (Panel on 
Guidance on Indicator Condition-Guided HIV 
testing in Adults 2012). 
Data existing so far are not sufficient to define 
whether there should be specific treatments of 
HIV infection in this stage of the disease com-
pared to earlier stages (i.e. more aggressive 
therapies? Use of drugs more prone to incre-
ment CD4? Others?). Interventions are need-
ed to clarify the main factors influencing late 
presentation and re-presentation in care, and 
which strategies to adopt to.
a) lower the impact of late presentation;
b) improve diagnosis assessment;
c) ameliorate immune-virological and clinical 
outcomes of late/AIDS presenters. 
The complexity of the disease in patients with 
late diagnosis requires a rapid control of HIV 
replication, a quick and effective improvement 
of immune functions, and, whenever present, 
control opportunistic infections, cancer, and 
all other clinical conditions associated with ad-
vanced HIV disease.
For all these reasons, a wide panel of treatment 
options should be made available for these pa-
tients, rather than just few standardized treat-
ments equal for everyone. All late-presenting 
patients should therefore undergo an individ-
ual treatment plan encompassing both antiret-
roviral therapy and, where necessary, treatment 
for opportunistic infectious, cancer and related 
pathologies. The choice of initial HIV treatment 
should reflect patient characteristics (including 
viroimmunological elements), the results of re-
sistance testing and the complexity of concom-
itant disease(s).
With regards to the resistance testing, HIV re-
sistance to antivirals, transmitted to naïve pa-
tients, is a phenomenon with important clinical 
implications, that may compromise initial an-
tiretroviral therapy if not properly considered 
(Little et al., 2002; Pozniak et al., 2006; Borro-
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to-Esoda et al., 2007). Indeed, studies clearly 
demonstrated that the virological response to 
a regimen selected on the basis of results of 
standard genotypic testing appears to be nearly 
as effective as the initial treatment of a patient 
without transmitted drug resistance, and in 
any case more effective than a regimen selected 
without resistance testing (Palella et al., 2009; 
Wittkop et al., 2011). For the above mentioned 
reasons, drug resistance testing before therapy 
starts, both in patients with acute infection and 
in those chronically infected, is considered the 
standard of care for the management of HIV-in-
fected individuals initiating ART (Hirsch et al., 
2008; Vandamme et al., 2011; Tang and Shafer 
2012; World Health Organization 2012c; San-
toro et al., 2013; Panel on Antiretroviral Guide-
lines for Adults and Adolescents 2014b).
In the management of a first line regimen, par-
ticular attention should be given to naïve HIV 
patients starting an antiretroviral regimen with 
a high baseline viral load. For a long time, the 
level of HIV-RNA >100,000 copies/ml has been 
identified as the unique threshold of high base-
line viral load to be considered for the evalua-
tion of the efficacy of different drug regimens. 
However, this definition of “high” viral load does 
not distinguish among groups that may differ 
biologically and functionally. Indeed, modern 
assays are able to quantify a wide range of viral 
loads above such level (100,000 to 10,000,000 
copies/ml). Recent studies show that patients 
starting their first line regimen with very high 
pre-HAART viremia (>500,000 copies/ml) have 
less probability of achieving and maintaining 
virological success (Armenia et al., 2013; San-
toro et al., 2013), thus reinforcing the impor-
tance of resetting the threshold of high vire-
mia, and of defining the different tiers of this 
parameter that may have clinical relevance (i.e. 
<100,000, 100,000-500,000, >500,000, etc.). 
Taken together, these findings reinforce the in-
dication in guidelines to consider high viremia 
levels an important parameter in setting both 
appropriate therapeutic strategies and the fre-
quency of viral load monitoring. Patients with 
very high pre-HAART viremia represent a sig-
nificant population that may deserve special 
attention. Ad hoc studies are needed to set the 
most appropriate strategies aimed at achiev-
ing the same high rate of therapeutic success 
in patients with high baseline viral load as that 
usually obtained in patients starting HAART at 
lower HIV-RNA levels. 
The same concepts may apply to immunologi-
cal parameters. As an example, the threshold of 
CD4 number may need to be further stratified, 
since having <10 CD4/ mm3 may not be equal, 
in terms of clinical outcome and therapeutic 
response, to having 190 CD4/ mm3 (both situa-
tions today generally defined as “advanced dis-
ease”). Limited data are available so far in this 
crucial area, particularly referring to the situa-
tion driven by recent and modern therapeutic 
approaches (that may have completely changed 
the results obtained in the past with old and less 
effective therapeutic regimens). Further studies 
are needed to define this important point.
Particular attention should also be given to pa-
tients with advanced HIV infection and neuro-
cognitive impairment (NCI). The determination 
of accurate incidence of neurocognitive impair-
ment and its progression during HIV infection 
remains a challenge (Mind Exchange Working 
2013) because to date there is no single well-es-
tablished and validated diagnostic biomarker 
or neuropsychological test to be used. 
The central nervous system (CNS) is a ma-
jor reservoir of HIV-1 (Schrager and D’Souza 
1998), and therefore represents an important 
target for antiretroviral therapy. Different class-
es of antiretroviral drugs appear to penetrate 
the CNS to differing degrees (McGee et al., 
2006; Tozzi et al., 2009; Winston and Garvey 
2009). Data from large randomized trials are 
needed to confirm the impact of antiretroviral 
regimens with greater CNS penetration on the 
improvement in neurocognitive performance, 
while issues of potential long-term neurotoxic-
ity require careful attention. Paradoxically, the 
ability of drugs to penetrate within the CNS is 
still challenged as a fundamental element for 
the success of antiviral therapy at the CNS lev-
el. Indeed, recent accumulating evidence sup-
ports either the key role of drug penetration, 
or the crucial importance of controlling HIV at 
systemic level. 
The role of earlier introduction of antiretroviral 
therapy and CNS-penetrating regimen for the 
prevention of HIV-associated neurocognitive 
impairment in high-risk patients still requires 
investigation.
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Finally, among the HIV-associated infectious 
comorbidities, both HBV and HCV infection re-
quire special attention since their natural evo-
lution may well impact both life duration and 
quality. In the last 10 years, dramatic advances 
have been made in the treatment of HBV (Cen-
ters for Disease Control and Prevention) and 
HCV (World Health Organization 2012a) infec-
tion and, particularly in the case of HCV infec-
tion, unprecedented cure rates are now achiev-
able with new drugs and regimens, while newer 
and even better options are being tested with ef-
ficacy expectations approaching 95% (Gane et 
al., 2013). Thus, new drugs and newer insights 
into human genetics are the main factors driv-
ing a revolutionary era in the management of 
chronic hepatitis (Aguilar Marucco et al., 2007; 
Ge et al., 2009; Tavel et al., 2010; Lange et al., 
2011; European Association For The Study Of 
The Liver 2012; Wilby et al., 2012; Bertelsen; 
Kieran et al., 2013; Zolopa et al., 2013). On the 
side of HIV-HCV co-infected patients, efforts 
are needed to improve the rates of inhibition of 
both viruses parallel the increased attention to 
the pathogenetic events determining liver fibro-
sis, and the molecules able to limit and control 
this phenomenon.
Since this chapter is dedicated to advanced pa-
tients with infectious co-morbidities, we should 
not forget the analysis of the classical infectious 
pathologies associated with HIV-driven immu-
nodeficiency. Toxoplasmosis, cytomegalovirus 
infection, cryptococcosis, atypical mycobacte-
riosis, and other opportunistic infections are 
still present and diagnosed in such patients, 
though their prevalence has dramatically 
dropped. Again, despite the late presentation 
(even today) of many HIV-infected patients, the 
rate of those having <50 CD4/ mm3 (a condition 
favoring such opportunistic infections) is lim-
ited. At the same time, pneumocystis jiroveci 
carinii pneumonia remains a problem in our 
patients at the time of late diagnosis. Finally, 
tuberculosis, particularly in immigrants, rep-
resents a growing infection at the time of late 
HIV-diagnosis. Taken all together, infections 
are still today aggravated by a significant rate 
of mortality in the first weeks after diagnosis. 
Dropping this mortality represents a main goal 
of the holistic approach to HIV infection, also 
including the improvement of earlier diagnosis 
Taken together, many challenges still remain 
while new ones appear in the extensive area of 
HIV patients with advanced infection and with 
infectious co-morbidities. These issues will be 
of even greater relevance if we consider the ex-
tended survival of HIV-infected patients and 
the difficulty (so far) in decreasing the rate of 
patients whose diagnosis of HIV infection is 
made at a very late stage. For these reasons, 
much attention must be given to new strate-
gies aimed at approaching the problem from a 
different perspective, with the aim of focusing 
on the epidemiological aspects of late infection 
and co-morbidities, and the potential solutions. 
HEFFICON has been designed with the pur-
pose of providing answers in this framework.
Late presenter or AIDS presenter patients
A. d’Arminio Monforte, C. Mussini
Evidence: The definition of late presentation 
was made by an International Consensus Con-
ference on the basis of the need to start antiret-
roviral treatment or not. As a consequence, ac-
cording to guidelines, a patient is considered a 
late presenter if the CD4 count at diagnosis is 
<350 cells/mm3 (Antinori et al., 2011). More re-
cently, national and international guidelines (in-
cluding WHO) bring forward the start of treat-
ment to a CD4 value <500 cells/mm3 (Thompson 
et al., 2012; World Health Organization 2013; 
Panel on Antiretroviral Guidelines for Adults 
and Adolescents 2014b). The definition of late 
presentation should then be modified accord-
ingly, possibly including only symptomatic pa-
tients or subjects with a CD4 count at presenta-
tion <200 cells/ mm3. Moreover, the cascade of 
care has shown that there is another population 
of patients presenting at a late stage of infection, 
i.e., those who are not engaged or not-retained 
in care after HIV infection diagnosis (Ndiaye et 
al., 2009; Mocroft et al., 2013b; Mugavero et al., 
2013). Several studies show how the cascade 
of care differs according to the health system 
(Figure 1 and Figure 2): even if in countries like 
Italy the rate of retention in care is higher than 
in the USA, the numbers are still high (Gardner 
et al., 2011; Lazzaretti et al., 2012).
One of the most important issues in HIV late 
presentation is how to identify subjects with 
HIV infection better and earlier and how to in-
crease the rate of testing in the population at 
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risk. As HIV infection spreads all over different 
strata of the population, there is no single be-
havioral hallmark of infection and virtually all 
age and socio-economic strata could be affect-
ed. However, higher risk subjects remain those 
with promiscuous sexual partnerships, inde-
pendently of gender. 
Late presentation is dangerous in terms of indi-
vidual and social health, and transverse efforts 
in planning common strategies at European 
level have been extensively carried forward. 
European guidelines have recently been de-
veloped to implement HIV testing in adults in 
public healthcare settings (Panel on Guidance 
on Indicator Condition-Guided HIV testing in 
Adults 2012). 
Basically, HIV testing is highly recommended 
to avoid late presentation of the disease, that 
may have at least three different clinical con-
sequences:
1) Late presentation may have significant ad-
verse implications in clinical management 
FIGURE 1 - The cascade of care in the 
USA (Gardner et al. 2011).
FIGURE 2 - The Cascade of care in 
the Modena cohort (Lazzaretti C. et al. 
HIV11, Glasgow 2012, abstract P105, 
ref 9).
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in case of cancers (commonly present at late 
stages of HIV disease).
2) Until the advanced disease occurs, there is 
more time and chances to transmit the virus 
through high-risk sexual behaviors.
3) The presence of diseases known to be asso-
ciated with immunosuppression that make 
the prognosis less favorable. 
In this regard, guidelines identify a list of dis-
eases associated with an HIV prevalence of 
>0.1%, and other conditions considered likely 
to have a HIV prevalence of >0.1%, that recom-
mend the testing of HIV (Table 1). Therefore, 
in all cases in which HIV infection can be sus-
pected (like those reported above), HIV testing 
is strongly recommended (Panel on Guidance 
on Indicator Condition-Guided HIV testing in 
Adults 2012). 
As a consequence, there is an urgent need for 
education of physicians from clinical areas 
other than infectious diseases. They should be 
educated to consider HIV testing a must when-
ever clinical symptoms falling in their area of 
expertise, known to be potentially associated 
with HIV infection (see above), may occur. This 
will increase the rate and appropriateness of 
HIV testing. 
Moreover, there still is a clear need to educate 
the general population on HIV symptoms and 
epidemiology. In a series of patients with newly 
diagnosed HIV infection in the UK, 76% out of 
263 patients had been in contact with their gen-
eral practitioner in the year prior to diagnosis, 
but only in 17% of them was the issue of pos-
sible HIV infection raised (Wohlgemut et al., 
2012). Similarly, in a ANRS survey, HIV testing 
was performed in a low percentage (<10-15%) 
of subjects with diseases considered HIV-asso-
ciated, such as generalized lymphadenopathy 
or recurrent bacterial pneumonia (Champenois 
et al., 2012). Existing data are not sufficient to 
define medical needs and the best treatment 
options in this population, and current guide-
lines do not specifically address this issue.
Population. On the basis of what was discussed 
above, the target population for the implemen-
tation of HIV testing also includes all patients 
with advanced HIV disease (i.e. those with a 
full-blown AIDS or with a CD4 count <200 cells/
mm3) not yet diagnosed, and, more in gener-
al, all those individuals with a high potential of 
transmission (see above), still unknown to be 
HIV positive, that may spread the infection to 
their sexual partners. 
Intervention. Interventions are needed to:
1) clarify the main factors influencing late pre-
sentation and re-presentation in care, and 
which strategies to adopt to lower the im-
pact of late presentation; ii) improve diagno-
sis assessment and immune-virological and 
clinical outcomes in this patient population. 
Some possible interventions that could be use-
ful to improve the management of late present-
ers:
TABLE 1 - Conditions associated with an undiagnosed HIV prevalence of >0.1 (A). 2b. Other conditions 
considered likely to have an undiagnosed HIV prevalence of >0.1% (adapted from HIV Indicator Conditions, 
(Panel on Guidance on Indicator Condition-Guided HIV testing in Adults 2012)).
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• Sexually transmitted infections
• Malignant lymphoma
• Anal cancer/dysplasia
• Cervical dysplasia
• Herpes zoster
• Hepatitis B or C (acute or chronic)
• Mononucleosis-like illness
• Unexplained Leukocytopenia/
thrombocytopenia lasting >4 weeks
• Seborrheic dermatitis/exanthema
• Invasive pneumococcal disease
• Unexplained fever
• Candidemia
• Visceral leishmaniasis
• Pregnancy (implications for the unborn 
child)
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• Primary lung cancer
• Lymphocitic meningitis 
• Oral hairy leukoplakia
• Severe or atypical psoriasis
• Guillan-Barré syndrome
• Mononeuritis
• Subcortical dementia
• Multiple sclerosis-like disease
• Peripheral neuropathy
• Unexplained weight loss
• Unexplained lymphoadenopathy
• Unexplained oral candidiasis
• Unexplained chronic diarrhea
• Unexplained chronic renal impairment
• Hepatitis A
• Community-acquired pneumonia
• Candidiasis
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1) Local data collection (maybe through a 
questionnaire) of the causes occurring in 
case of late presentation of HIV, or non-en-
gagement in care.
2) Periodical surveillance in all centers to iden-
tify patients lost to follow-up and telephone 
calls to try to re-engage patients in care.
3) A drug utilization study to better understand 
the approach to treat this population and re-
lated outcomes.
4) A systematic review to identify medical 
needs and the best treatment regimens ac-
cording to short-term immune-virological 
outcomes. 
Moreover, it must be taken into consideration 
that late/AIDS presenters should promptly 
start a potent, highly effective and rapid treat-
ment, in order to reduce all consequences re-
lated to the immune-virological and clinical 
conditions typical of this stage of infection. 
In this population cluster, the major aim of 
treatment is to preserve organs and systemic 
functionality from further deterioration. This 
could be achieved with a therapeutic approach 
beyond traditional and consolidated regimens, 
such as administering more than 2 ARV drug 
classes or using/combining last generation 
ARV drugs.
Outcome. Expected outcome is to identify a 
number of HIV positive individuals at an ear-
lier stage of infection, who thus could benefit 
from ART treatment and could reduce their in-
fectious potential.
Moreover, other expected outcomes of the pro-
posed interventions could be:
a) development of targeted local campaigns, 
on the basis of the obstacle to testing that 
will likely emerge from the questionnaire;
b) local strategies to increase retention in care;
c) identification of the best possible regimens 
to be tested in randomized clinical trials.
Resistance transmitted to naïve patients
C.F. Perno, M.S. Santoro 
Evidence. A substantial number of studies 
have been performed across the world to deter-
mine HIV drug resistance transmitted to naïve 
patients (transmitted drug resistance, TDR) 
(Vercauteren et al., 2009; Wheeler et al., 2010; 
Agwu et al., 2012; Castor et al., 2012; Frentz et 
al., 2012; World Health Organization 2012d). 
This is a phenomenon with important clinical 
implications that may compromise initial an-
tiretroviral therapy if not properly considered 
(Little et al., 2002; Pozniak et al., 2006; Borro-
to-Esoda et al., 2007; Kuritzkes et al., 2008). 
Therefore, in the whole developed world, drug 
resistance testing before therapy starts both 
in patients with acute infection and in those 
chronically infected is considered the standard 
of care for the management of HIV-infected 
individuals initiating ART (Hirsch et al., 2008; 
Vandamme et al., 2011; Tang and Shafer 2012; 
World Health Organization 2012c). 
Levels of TDR are consistent throughout the 
world with some differences driven by several 
factors including the rate of therapeutic suc-
cesses in each country, and the time to start an-
tiviral therapies (that in turn may reduce the 
number of patients able to transmit resistant 
virus). In addition, some variations over time 
of the rate of resistance occur, again reflecting 
the above-mentioned factors as well as chang-
es in the prescription of antiretrovirals (ARVs) 
(Vercauteren et al., 2009; Wheeler et al., 2010; 
Agwu et al., 2012; Castor et al., 2012; Frentz et 
al., 2012; World Health Organization 2012d; 
Panel on Antiretroviral Guidelines for Adults 
and Adolescents 2014b). 
Data suggest that up to 10-17% of ART-naïve 
HIV-infected individuals living in Australia, Ja-
pan, North America and Europe are infected 
with a virus resistant to at least one ARV class 
(World Health Organization 2012d). These 
levels of TDR occurred early after ART was 
introduced in many high-income countries in 
the late 1990s, but have since then plateaued 
and, in some cases, decreased. The proportion 
of people achieving virological suppression in-
creased over time, thus reducing the emergence 
of acquired drug resistance and its subsequent 
transmission. 
Although lower proportions of TDR were found 
in Latin America (6.3%), Africa (4.7%), and 
Asia (4.2%) (Castor et al., 2012), studies have 
reported prevalence rates as high as 10% in 
localized areas (Hamers et al., 2011; Price et 
al., 2011; Thorat et al., 2011; Tshabalala et al., 
2011). Moreover, transmitted NNRTI gradual-
ly increased in recent years in resource-limited 
settings (Frentz et al., 2012; Gupta et al., 2012; 
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World Health Organization 2012d). This can be 
explained by the ARVs becoming more available 
during recent years in these continents. In this 
regard, HIV-1-infected individuals in countries 
in which ART had been available for at least 5 
years were 1.7 times more likely to have TDR 
than those living in a country where ART had 
been available for less than 5 years (P<0.001) 
(Stadeli and Richman 2013). There is no clear 
evidence of increasing TDR levels to ARV class-
es different than NNRTI.
A variation of TDR prevalence among different 
HIV risk groups is found. For example, homo-
sexual individuals are more likely than hetero-
sexual individuals to be infected with drug-re-
sistant HIV. One potential explanation, though 
not fully exhaustive, is that individuals who 
acquired HIV through heterosexual contact are 
(still) more likely to come from regions with 
limited access to ARVs (Vercauteren et al., 2009; 
Frentz et al., 2012).
Current American and European HIV guide-
lines recommend that drug resistance testing 
should be performed when a patient is first di-
agnosed with HIV-1 (Hirsch et al., 2008; Van-
damme et al., 2011; Panel on Antiretroviral 
Guidelines for Adults and Adolescents 2014b). 
In newly diagnosed patients, a delay in testing 
would increase the risk that a TDR mutation 
would decrease in its proportion relative to 
the fitter wild-type revertants, and therefore 
no longer be detected by standard genotypic 
resistance testing, which cannot consistently 
detect variants present at levels below 20% of 
the plasma virus population. In patients who 
defer treatment, repeat genotypic resistance 
testing should be considered if the patient is at 
high risk of having been superinfected. More-
over, in patients with TDR, the test before the 
ART starts may supply information on the viral 
evolution and kinetics of disappearance of mu-
tations. 
Standard genotypic drug resistance testing in 
ART-naïve individuals involves testing for mu-
tations in the protease and reverse transcrip-
tase genes. Although transmission of integrase 
strand transfer inhibitor (INSTI)-resistant vi-
rus has rarely been reported, as use of INSTIs 
increases the potential for transmission of IN-
STI-resistant viruses may also increase (Cos-
sarini et al., 2011; Hurt 2011). Therefore, for 
naïve HIV-1 individuals whose infection with 
HIV carrying INSTI resistance is suspected (be-
cause the source of infection is known, as an 
example), genotypic resistance testing also for 
this drug class should be considered (Panel on 
Antiretroviral Guidelines for Adults and Ado-
lescents 2014b).
Population. The evaluation of TDR is definite-
ly important for all HIV-1-infected subjects 
(both in acute or chronic infection) at their en-
try into care regardless of whether ART will be 
initiated immediately or deferred. This analy-
sis needs to be carried out in order to charac-
terize the virus before the therapy starts, and 
therefore to limit the risk of virologic failure 
(Little et al., 2002; Pozniak et al., 2006; Bor-
roto-Esoda et al., 2007). Indeed, studies clear-
ly demonstrated that the virological response 
to a regimen selected on the basis of results 
of standard genotypic testing appears to be 
almost as effective as the initial treatment of 
a patient without TDR, and in any case more 
effective than a regimen selected without re-
sistance testing (Palella et al., 2009; Wittkop et 
al., 2011; Santoro et al., 2013).
Intervention. In regions where initial genotyp-
ic resistance testing is not readily available, ap-
propriate campaigns of primary drug resistance 
surveillance should be performed in order to 
identify populations at high risk for TDR, for 
whom ART recommendations may need to be 
modified or for whom baseline resistance test-
ing should be considered (Jordan et al., 2012; 
Tang and Shafer 2012).
Outcome. TDR is associated with suboptimal 
virologic response to initial ART (Little et al., 
2002; Pozniak et al., 2006; Borroto-Esoda et al., 
2007; Kuritzkes et al., 2008). Therefore, data 
on HIV TDR (both at the population level, and 
at the single patient level) provide the basis 
for selecting correct first line regimens. TDR 
is also predicted to have a potentially signifi-
cant impact on future HIV mortality (Bertag-
nolio et al., 2013; Cambiano et al., 2013). For 
the above-mentioned reasons, it is critical to 
remain vigilant over transmission of drug-re-
sistant HIV, even at our time when many ther-
apeutic options are available, and the issue of 
resistance seems to be no longer as relevant as 
it was in the past.
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Naïve patients with high viral loads
S. Bonora, P. Cinque
Evidence. The level of HIV-RNA >100,000 cop-
ies/ml has been identified as the threshold of 
high baseline viral load (VL) and is currently 
considered a key point to evaluate the perfor-
mance of different regimens in naïve patients. 
In most recent trials, virological efficacy in pa-
tients starting treatment with VL above 100,000 
copies/ml was lower than in those starting be-
low 100,000 copies/ml, with a significantly low-
er achievement of virological success for some 
drugs (e.g. lower virological response to Rilpi-
virine as compared to Efavirenz in ECHO and 
THRIVE, and of Darunavir/Ritonavir as com-
pared to dolutegravir in FLAMINGO) (Cohen 
et al., 2011a; Molina et al., 2011; Clotet et al., 
2014). However, the choice of this threshold 
was based on methodological criteria (i.e., up-
per level of HIV-RNA quantification of previous 
assays and/or median of study populations) 
rather than biological or functional parameters. 
In the clinical setting, the question is whether 
100,000 copies/ml is the real VL threshold to be 
considered in difficult-to-treat patients. Some 
trials, such as the STAR study comparing ril-
pivirine and efavirenz both in a single tablet 
regimen with tenofovir/Emtricitabine (TDF/
FTC) showed that the risk of virological fail-
ure previously associated with viremia above 
100,000 copies/ml is restricted to patients with 
very high baseline viremia, specifically above 
500,000 copies/ml (Cohen et al., 2013). There-
fore, the current definition does not distinguish 
between groups that may differ biologically and 
functionally, while modern assays are able to 
quantify a wide range above such level (100,000 
to 10,000,000 copies/ml). As a consequence, pa-
tients with viremia levels >100,000 copies/ml 
are included but poorly characterized in clin-
ical trials. Yet, predictors of virological effica-
cy in this population have not been specifically 
studied.
Moreover, recent data suggest that achievement 
of VL <50 copies/ml is proportionally slower in 
patients starting with viremia >100,000 copies/
ml (especially at viremia >500,000 copies/ml) 
(Santoro et al., 2013), and this could also im-
pact on the definition of virological success as 
the achievement of VL <50 copies/ml both at 
week 24 in the clinical setting or at week 48 ac-
cording to time to loss of virological response 
(TLOVR) or snapshot analysis in trial condi-
tion. In fact, the slower achievement of VL <50 
copies/ml target could impact on TLOVR, while 
Snapshot analysis could be affected by more 
frequent viral blips observed in patients with 
high viral loads. 
In conclusion, there is a substantial lack of clin-
ical trials specifically designed for patients with 
high viral load and classical endpoints of effi-
cacy, e.g., viral load at 48 weeks might not be 
adequate in patients with high viral loads.
Population. Naïve HIV positive patients start-
ing HAART with baseline viral load above 
100,000 copies/ml. Patients will need to be dif-
ferently grouped accordingly to CD4 cell count, 
demographics, comorbidities and other vari-
ables.
Intervention. A review of current literature 
through meta-analysis studies or design of ob-
servational or cohort studies, and, depending 
on feasibility, randomized clinical trials, aim-
ing to:
- define with more accuracy “patients with 
high viral load”, taking into consideration 
viremia strata above 100,000 copies/ml;
- define criteria and endpoints of virological 
success to use in the clinical setting accord-
ing to the level of baseline viral load;
- identify predictors of virological response 
among subjects with viral load >100,000 
copies/ml (adherence, CD4 count, gender, 
PK, comorbidities, etc.) not yet captured by 
clinical trials;
- identify new biomarkers complementary 
to viral load assessment and predictors of 
treatment responses; 
- assess the impact of virological response on 
clinical outcomes (clinical events, mortality, 
immune reconstitution);
- assess the frequency of selection of resis-
tance at failure according to viral load strata 
>100,000 copies/ml;
- evaluate therapeutic approaches specifically 
targeting difficult-to-treat patients with high 
viral loads such as:
1) adapted dosing or schedule of selected 
drugs;
2) alternative triple class regimens (e.g. com-
bining more than 2 classes of drugs and in-
tegrase inhibitors (INI));
HEFFICON: HIV Effectiveness Italian Conference 161
3) induction and maintenance strategies (e.g. 
initial 4-drugs regimen);
4) alternative methods of administration of po-
tent drugs with a high genetic barrier (e.g. 
dolutegravir) to improve compliance and 
better maintain appropriate plasma drug 
levels (e.g. single tablet regimen with nov-
el drug combination, long-acting injectable 
combinations).
Outcome. The final outcome is setting the most 
appropriate strategies to equal in patients with 
high baseline viral loads, the rate of therapeu-
tic success usually obtained in patients starting 
HAART at lower HIV-RNA levels.
Patients with neurocognitive impairment
C. Mastroianni
Evidence. The global prevalence of HIV-associ-
ated neurocognitive impairment (NCI) has not 
changed from the pre– to the potent ART era, 
remaining at approximately 50% (Heaton et al., 
2010). In this respect, there has been a decline 
in HIV-associated dementia (HAD) (from 18% 
to <5%), whereas the prevalence of mild or as-
ymptomatic NCI was stable or even increased 
to about 20-30% (Ellis et al., 2007; Tozzi et 
al., 2007). Fluctuations of NCI may occur and 
about 30% of patients change their neurocog-
nitive status (improving, declining, or fluctuat-
ing) over time (Antinori et al., 2007).
An accurate determination of the incidence of 
NCI and its progression during HIV infection 
remains a challenge (Mind Exchange Working 
2013) because to date there is no single well-es-
tablished diagnostic biomarker or neuropsy-
chological test to be used. In particular, there 
is no standard validated easy-to-perform test to 
screen for mild NCI in all HIV-infected patients. 
There are insufficient data to establish the best 
time for follow-up assessments and the effect 
of treatment and preventive measures on HIV 
neurocognitive impairment. Finally, there are 
no systematic studies addressing in what extent 
neurocognitive impairment may be reversible 
or remains permanent.
Population. The identification and differen-
tial diagnosis of HIV-associated NCI in clini-
cal practice should take into consideration all 
HIV-infected patients with the following evi-
dence-supported risk factors:
a) disease factors (low nadir CD4 count, 
high-level of HIV replication, past CNS in-
fections);
b) treatment factors (poor adherence, incorrect 
ART regimen, potential ART neurotoxicity);
c) AIDS and non-AIDS comorbidities;
d) demographic factors (aging, low socio-eco-
nomic status);
e) other neurological and psychiatric disor-
ders. 
Intervention. Short and validated monitoring 
tools for NCI are needed for follow-up assess-
ment of HIV-associated NCI. Cerebrospinal 
fluid (CSF) analysis should be performed in 
patients with neurological symptoms or signs 
but it remains to be addressed whether this is 
indicated in patients with asymptomatic NCI. 
Studies that better clarify the role of some vi-
rological tests (e.g. HIV-DNA), biomarkers of 
immune activation and neurological injury as 
well as neuroimaging or neurophysiologic as-
sessment should be strongly encouraged. Data 
from large randomized trials are needed to con-
firm the impact of ART regimens with greater 
CNS penetration on the improvement in neu-
rocognitive performance, while issues of poten-
tial long-term neurotoxicity require careful at-
tention. Finally, the role of earlier introduction 
of cART and CNS-penetrating regimen for the 
prevention of HIV-associated NCI in high risk 
patients should be investigated.
Outcome. Final outcomes include the prompt 
identification of patients with HIV-associated 
NCI, correct follow-up assessment and appro-
priate therapeutic and preventive strategies.
Patients with HBV/HCV coinfection
G. Di Perri, M. Puoti
Evidence: Among the HIV-associated infec-
tious comorbidities both HBV and HCV infec-
tion require special attention since their natural 
evolution may well impact on both life dura-
tion and quality. In the last 10 years, dramat-
ic advances have been made in the treatment 
of HBV (Centers for Disease Control and Pre-
vention) and HCV (World Health Organization 
2012a) infection and, particularly in the case of 
HCV infection, unprecedented cure rates are 
now achievable with new drugs and regimens, 
while newer options are being tested with ef-
ficacy expectations approaching 95% (Gane et 
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al., 2013). Thus new drugs and newer insights 
into human genetics are the main factors driv-
ing a revolutionary era in the management of 
chronic hepatitis. 
The treatment of HBV infection with nucle-
oside/nucleotide analog inhibitors of reverse 
transcriptase (N/NtRTIs) provide in most cas-
es full inhibition of HBV replication together 
with normalization of liver enzymes levels and 
a substantial interruption of the chronic evolu-
tion of liver fibrosis .
In parallel with the development of TAF 
(alafenamide, formerly GS7340) for anti-HIV 
treatment, interest is also focused on having 
the drug available for anti-HBV therapy. TAF 
is a new prodrug of TDF, showing more po-
tent anti-HIV-1 activity and higher intracellular 
TDF levels compared with tenofovir disoprox-
il fumarate, while maintaining lower plasma 
tenofovir exposure at 40 mg with good tolera-
bility over 14 days of monotherapy (Markow-
itz et al., 2014). Moreover TAF provides signifi-
cantly reduced renal tubular toxicity (Sax et al., 
2013). Recent studies highlighted that TAF also 
leads to higher levels of active tenofovir in he-
patocytes (liver cells) (Agarwal et al., 2013) and 
shows an antiviral activity similar and compa-
rable to TDF also in HBV-infected patients (6). 
The use of this antiviral in HIV/HCV-coinfected 
patients should therefore be investigated. 
The two available pharmaceutical forms of pe-
gylated interferon (PEG-IFN) are among the 
therapeutic weapons in both anti-HBV and 
HCV treatment. Currently, treatment for chron-
ic HCV infection in HIV-positive patients is still 
based on interferon (IFN) and ribavirin (RBV), 
that are the recommended treatment for HCV 
genotypes 2, 3 and 4 (European AIDS Clinical 
Society Guidelines (EACS) 2013). It should also 
be taken into account that IFN in HIV positive 
patients could determine a reduction in CD4 T 
cell count of different magnitude. However, no 
descriptions of IFN effects on plasma HIV-RNA 
have ever been detailed. In an Italian experi-
ence the treatment of HCV chronic hepatitis in 
HIV-infected patients not taking antiretrovirals 
was analyzed to evaluate the effects of IFN ad-
ministration on HIV-related immunovirologi-
cal parameters. Further to the expected CD4 T 
cell count decrease, a significant drop in HIV-
RNA was also seen, with median (range) HIV-
RNA decline of –1.46 (2.75; –0.22), –1.43 (–2.84; 
0.21), and –1.07 (−2.46; 0.62) log10 copies/ml at 
2, 4 and 12 weeks, respectively (Aguilar Maruc-
co et al. 2007). Although major attention should 
be paid to the CD4 T cell count decrease, such 
a significant antiretroviral effect might to some 
extent compensate for the transient numerical 
decrease of CD4 T cells (Tavel et al., 2010).
Like antiretroviral treatment, anti-HCV thera-
py is now also based on three-drug regimens, 
as the validated PEG-IFN/RBV backbone has 
been successfully associated with a third anti-
viral drug, either Boceprevir (BOC) or Telapre-
vir (TLV), with cure rates above 70% in HCV 
genotype 1 (Kieran et al., 2013). HCV direct-act-
ing antiviral agents (DAA)-based therapy with 
either BOC or TLV is now the new standard 
of treatment in HCV genotype 1 infection in 
HIV-positive persons where available.
Both these new DAAs are substrates of isoen-
zyme CYP3A, on which they exert an inhibitory 
effect. This translates into some defined drug-
drug interactions, also including antiretrovi-
rals, and caution must be observed in case of 
co-administration with drugs sharing this met-
abolic pathway (Wilby et al., 2012; Bertelsen 
2013). 
IFN-free regimens can also theoretically be 
used in HIV-positive patients coinfected with 
HCV and are expected to achieve high SVR 
rates, though further investigation is needed 
(European Association For The Study Of The 
Liver 2012). 
The study of human genetics is providing im-
portant new information on both the sponta-
neous outcome of untreated HCV infection as 
well as the likelihood of treatment response to 
anti-HCV treatment. Interleukin 28 polymor-
phisms (IL28B) and additional genetic varia-
tions in regions coding for factors included in 
the process of activation/enhancement of cellu-
lar immune response (e.g. vitamin D promoter) 
are shedding light on potentially pre-classifying 
patients before any specific anti-HCV regimen 
is chosen (Ge et al., 2009; Lange et al., 2011). 
These findings are thus paving the way to indi-
vidualized therapy, with possible achievements 
in terms of lower rates of untoward effects as 
well as a reduction in drug expenditure. 
Regardless of the therapeutic regimen, a unique 
window of opportunity to get rid of evolving 
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HCV infection is the treatment of acute infec-
tion. Cure rates may be as high as 75% with 
just PEG-IFN even in patients being infected 
with HCV-genotype 1 (De Rosa et al., 2006). No 
definite recommendations have so far been re-
leased on how to manage acute HCV infection 
(spontaneous clearance is also an occurrence 
taking place with significant frequency), but ac-
cording to few published case series the chance 
of sustained virological response (SVR) is on 
the average higher than in case of chronic in-
fection, and this also applies to HIV-HCV-coin-
fected patients.
Among the drugs approved against HIV infec-
tion, the potential anti-fibrotic effects of mar-
aviroc (MVC), a CCR5-specific HIV entry in-
hibitor, is currently exploited. In a comparative 
Italian study on HIV-HCV patients MVC was 
added as 4th drug to a successful antiretroviral 
regimen consisting of ritonavir-boosted ataza-
navir and TDF/FTC, while controls remained 
on the original regimen. Improvement in liver 
stiffness was seen in the study arm (Nasta et 
al., 2011). MVC has been also found to reduce 
chronic inflammation and immune activation, 
atherogenesis and hepatocellular carcinoma 
(Sauzullo et al., 2010; Ochoa-Callejero et al., 
2013). Should any of these properties be con-
firmed to play a clinically relevant role, MVC 
might become a “multitask” drug to be consid-
ered in chronic infections.
Population: All naïve HIV-positive individu-
als who are coinfected with HBV and/or HCV. 
These patients warrant aggressive treatment 
against both HIV and hepatitis viruses to re-
duce the rate of liver-specific disease and death. 
Intervention: A review of current literature 
through meta-analysis studies or design of ob-
servational or cohort studies, and, depending on 
feasibility, randomized clinical trials, aiming to:
- Evaluate the efficacy and safety of TAF in 
HIV/HBV-coinfected patients. 
- Evaluate the HBV genetic background in 
modulating the virological response to TAF. 
In this regard, it is already known that a high 
degree of HBV genetic variability can lead to 
the emergence of viral strains with a natu-
ral resistance to tenofovir in HIV/HBV-coin-
fected patients, even if at low-level (Lada et 
al., 2012). Thus, HBV-genotypic testing can 
help identifying patients at risk of disease 
progression and thus patients who need an 
early and highly effective treatment.
- Evaluate the potential drug-drug interac-
tions between DAAs and antiretrovirals and 
mechanisms related to the reduction of an-
tiviral activity determined by these interac-
tions in HIV/HCV-coinfected patients. 
- Assess the best treatment choice including 
the novel anti-HCV drugs used with or with-
out IFN/RBV. 
- Evaluate molecules among the drugs used 
against HIV infection able to limit the patho-
genetic events determining liver fibrosis. In 
this frame, more studies are required to con-
firm the potential anti-fibrotic role of MVC. 
- Evaluate the role of other human polymor-
phisms (a part from IL28) in the control of 
HCV infection in the context of HIV infec-
tion. 
Outcome: The final outcome is setting the most 
appropriate strategies to improve quality of life 
and reduce the rate of liver specific-disease and 
death in HIV-positive patients coinfected with 
HBV or HCV.
3 - PATIENTS WITH NON-INFECTIOUS 
COMORBIDITIES
Coordinator A. Antinori
Introduction
Following the impact of cART on the disease 
natural history and considering prolonging sur-
vival, AIDS-defining conditions are increasing-
ly rare in patients receiving cART and present-
ing persistent suppressed HIV viremia (Mocroft 
et al., 2013a). By contrast, the list of HIV-associ-
ated non-AIDS conditions as non-infectious co-
morbidities is growing (High et al., 2012). Sev-
eral of these conditions are strongly associated 
with advancing age and chronic inflammation, 
and include cardiovascular disease, non-infec-
tious cancers, osteopenia and osteoporosis, 
liver disease, renal disease and neurocognitive 
impairment (Sulkowski and Thomas 2003; Lu-
cas et al., 2007; Silverberg et al., 2009; Freiberg 
et al., 2011; Womack et al., 2011; Silverberg et 
al., 2012).
Evidence from randomized and observational 
studies indicates that both HIV infection and 
ART may influence morbidity and mortality 
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through effects on inflammation, treatment-re-
lated toxicities (such as renal, bone, and ef-
fects on cardiovascular risk disease), complex 
interactions with other chronic viral infec-
tions (as CMV infection), and non-infectious 
comorbidities like those typically associated 
with increased aging (Deeks et al., 2013). For 
all these reasons, HIV-infected persons exhibit 
an excess burden of co-morbid conditions and 
the premature onset of clinical symptoms and 
syndromes, very close to those typically associ-
ated with advanced aging, multimorbidity, and 
polypharmacy (High et al., 2012).
Moreover, it is well known that chronic inflam-
mation plays a central role in the pathogenesis 
of untreated and ART-treated HIV infection. In 
fact, HIV replication directly contributes to T 
cell activation (Papagno et al., 2004). Moreover, 
the HIV-mediated breakdown in the gut muco-
sa produces chronic exposure to gut microbial 
products like lipopolysaccharide (LPS) that may 
be a recognized factor driving inflammation 
(Brenchley et al., 2006). Finally, dysfunctional 
immunoregulatory factors may contribute to 
sustain a picture of persistent inflammation. 
The chronic inflammatory environment may 
cause fibrosis in lymphoid tissues, with CD4 T 
cell regenerative failure and persistent chron-
ic dysfunction and disease (Zeng et al., 2012). 
cART only partially reverses many of these 
proinflammatory pathways, but the effect is 
still largely incomplete, and inflammation may 
indefinitely persist.
It is well known that monoctye turnover and ac-
tivation could be directly linked to HIV patho-
genesis. Soluble CD14 (sCD14) and CD163, 
recognized monocyte activation markers, were 
found elevated in HIV disease and were both 
predictive of increased morbidity and mortal-
ity in the HIV-infected population (Burdo et 
al., 2011). sCD14 can bind LPS and deliver it 
to vascular endothelial cells, promoting their 
activation by LPS. CD163, the hemoglobin 
scavenger receptor, is expressed on the mono-
cytes surface, particularly those that are more 
inflammatory (CD14+CD16+). CD163 is re-
leased as a soluble form (sCD163) in response 
to a number of inflammatory signals. Activated 
(CD14+CD16+) monocytes are frequently ele-
vated in untreated and treated HIV disease, and 
proinflammatory CD16+ monocytes may be 
related to an increased risk of coronary artery 
calcium progression. All these observations 
support the hypothesis that chronic activation 
of innate immunity may contribute to enhance 
morbidity and mortality in HIV-infected adults 
even successfully treated by antiretroviral 
drugs. Persistent levels of ongoing HIV replica-
tion during ART exposure may impact immune 
activation and chronic inflammatory activation 
pathway, and progressively increase the risk of 
comorbidities even in ART-treated individuals.
Chronic upregulation of these immunologic 
pathways may cause disease. It has been as-
sessed that monocyte and macrophage relat-
ed inflammation pathways are crucial for the 
pathogenesis of atherosclerosis even in the gen-
eral population. In the HIV-infected population, 
chronic enhanced inflammation, altered blood 
flow dynamics, circulating bacterial products, 
proatherogenic lipids (related to toxic pro-
longed effects of antiretroviral drugs exposure), 
and other factors associated with HIV infection 
can cause endothelium damage and upregula-
tion of adhesion factors. Monocytes are recruit-
ed in blood vessel walls and may contribute to 
the formation of atherosclerotic plaques.
Further, HIV infection may causes a hypercoag-
ulable state, strongly related to chronic inflam-
mation and enhancing the risk of comorbid 
conditions. The role of hypercoagulability as 
a cause of morbidity and mortality in HIV-in-
fected individuals was recognized after demon-
stration that D-dimers strongly correlate with 
all-cause mortality (Kuller et al., 2008). Several 
studies confirmed the association of D-dimers 
with mortality, occurrence of cardiovascular 
disease (Duprez et al., 2012), as well as venous 
thromboembolic disease (Musselwhite et al., 
2011). The model of evidence on hypercoagu-
lation as a direct cause of morbidity, already 
recognized in the general population, may be 
transferred to the HIV disease setting. From a 
pathogenetic point of view, HIV persistent rep-
lication, even at a low-level, may affect hyper-
coagulation and induce an increase in D-dimer 
levels. The rate of HIV replication could cor-
relate with D-dimer levels in untreated disease 
(Calmy et al., 2009), and several studies demon-
strated that starting cART may be associated 
with a reduction in levels of D-dimer (Palella et 
al., 2010), although this reduction effect during 
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treatment is not sufficient to reverse D-dimer 
amounts to preinfection levels, as suggested 
by comparative measurements in non-infected 
controls. Intensification studies with an addi-
tional potent antiretroviral drug (e.g. INSTI) 
in the context of a successful cART regimen 
may decrease ongoing HIV replication and 
produce a decrease of D-dimer levels (Hatano 
et al., 2013a). Finally, chronic inflammation 
related to untreated or persistently low-level 
replication of infection may also be related to 
enhanced coagulation status, as demonstrated 
by the observation that more elevated circulat-
ing levels of sCD14 and sCD163 are associated 
with increased D-dimer levels (Funderburg et 
al., 2010).
In the HIV setting, advances in knowledge 
could be driven by the use of biomarkers. Sev-
eral biomarkers have been suggested as pre-
dictive of an increased comorbidities burden 
or organ diseases in the HIV population. Nev-
ertheless, the degree to which these biomark-
ers really have prognostic characteristics in 
HIV-infected people is still largely unknown. 
This is also true considering the problems in 
identifying cohorts of behaviorally and demo-
graphically similar infected and uninfected 
adults. Many biomarker studies reported to 
date have included untreated and treated HIV 
individuals, despite the fact that HIV replica-
tion is known to be a major determinant of 
inflammation, immune function, and overall 
health. Unfortunately, even those studies that 
focused on long-term treated individuals rarely 
controlled for the degree of viral suppression. 
Further, behavioral aspects may affect both 
biomarker behavior and the risk of non-AIDS 
morbidity and mortality, and this may be a fur-
ther confounder of study design and results. A 
priority in the development of biomarkers and 
clinical prognostic indices (such as the Veter-
ans Aging Cohort Study Index (VACS)) are to 
identify those biomarkers indicative of resid-
ual disease (in terms of immune activation, 
immunologic dysfunction and chronic in-
flammation), to characterize the link between 
chronic inflammation and persistent immu-
nodeficiency during treatment, and to analyze 
the size effect of both modifiable risk factors 
for non-infectious comorbidities and chronic 
HIV infection.
Randomized clinical trials will need to test the 
increased approaches to aging and comorbidi-
ties in the HIV-infected population. The studies 
should focus on management strategies or indi-
vidual interventions and involve a combination 
of behavioral and therapeutic approaches. ART 
initiation trials may test the impact of health 
interventions, and the effectiveness of these in-
terventions related to the rate of patient adher-
ence to ART. Innovative methods of performing 
trial design may allocate the HIV population 
to standard care versus medical management 
guided by the VACS Risk Index or frailty phe-
notype, and address signs of cardiovascular, liv-
er, renal, and bone injuries. Further, proof-of-
concept small intensive trials should be used to 
identify interventions that reduce HIV-associat-
ed inflammation and/or immune activation in 
order to progressively move into larger studies 
characterized by clinical endpoints focused on 
morbidity occurrence and survival.
Patients with chronic inflammation 
and cardiovascular risk: role of biomarkers
P. Maggi, M. Galli
Evidence. HIV infection is associated with 
numerous co-morbidities, whose incidence 
increases with patient age, allowed by the suc-
cess of antiretroviral therapy. Therapy itself is 
considered to be involved in the pathogenesis 
of some of these, leading to an increased and 
earlier incidence than in the general popula-
tion. HIV infection can be considered a typical 
example of a chronic inflammatory disease, 
characterized by a persistent and aberrant ac-
tivation of the immune system induced by HIV 
as well as a wide range of non-HIV-related 
stimulations. An early loss of gut mucosal in-
tegrity, the pro-inflammatory cytokine milieu, 
co-infections and the progressive disruption of 
lymph node architecture contribute to deter-
mine a permanent activation of both the innate 
and adaptive immune systems. CD4 T cell loss, 
induced by providing an additional substrate 
for viral infection in the form of activated CD4 
T cells and by priming non-infected ‘bystander’ 
CD4 T cells for death by apoptosis, is one of the 
major consequences of such persistent immune 
activation (Ipp and Zemlin 2013).
Chronic inflammation is a major cause of can-
cer and aging and is involved in the pathogen-
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esis of a wide variety of age-related diseases, 
such as diabetes, cardiovascular and autoim-
mune disorders (Khansari et al., 2009). 
Immunity deregulation and chronic inflamma-
tion can be considered key driving forces also 
for non-HIV-related complications such as car-
diovascular, kidney and bone, liver, lung, CNS 
disease and cancer. It is debated whether the 
incidence of some non-HIV-related co-morbid-
ities is anticipated or simply enhanced or both. 
However, the incidence of some aging-related 
disorders is reported to increase despite a good 
response to ART.
Population. In a scenario where therapy 
should be continued for the entire lifespan du-
ration of each patient, the whole population of 
people with HIV infection should be submitted 
to a careful clinical screening and laboratory 
monitoring designed to assess the individu-
al risk of developing comorbidities associated 
with the persistence of a chronic inflammato-
ry state. Although this indication can be ap-
plied to the entire HIV positive population, 
advanced naïve patients, people over 50 years 
and, for some pathological conditions, meno-
pausal women are considered by many experts 
as groups deserving special attention. Particu-
lar consideration is also given to those with or 
at risk of coinfections such as HBV, HCV, HPV. 
The importance of the use of biomarkers of 
inflammation is discussed and investigated in 
this context. 
For these reasons, the elaboration of algorithms 
based also on inflammation biomarkers as well 
as the identification of cost-effective markers 
of inflammation to be used to predict the risk 
of inflammation-related comorbidities  repre-
sent hot topics for current and future research. 
Intervention. The candidate biomarkers cur-
rently under investigation to improve the as-
sessment of the cardiovascular risk in HIV pa-
tients include CRP, IL-6, VCAM, ICAM, VWF, 
D-dimer and ADMA. 
A possible challenge complicating the use 
of such biomarkers is the different behavior 
shown by some of them (e.g., IL-6, sCD14) 
in HIV disease and in the general population 
(Neuhaus et al. 2010). The association of an in-
creased level of inflammation biomarkers and 
the subsequent morbidity/mortality is some-
times stronger in HIV-infected compared to 
HIV-uninfected individuals. For example, the 
adjusted odds ratios of mortality associated 
with abnormal levels of sCD14, IL-6 and D-di-
mer observed in the SMART study (Kuller et 
al., 2008) were significantly higher than those 
observed in the general population, but the 
risks associated with increased CRP levels were 
much lower than might be expected given the 
IL-6 data. 
Nevertheless, the role of IL-6 and D-dimer 
levels as powerful predictors of non-AIDS co-
morbidities and death was recently confirmed 
combining the data of 3 large clinical trials 
(SMART, ESPRIT, and SILCAAT) (Grund et al., 
2013). The authors also proposed an equation 
including both parameters which is more pre-
dictive of clinical events and death than each 
of them considered separately. This equation 
should be validated in prospective studies and 
could be used to design clinical trials aimed at 
reducing chronic inflammation. 
IL-6, D-dimer and sCD14 (markers of inflam-
mation, coagulation and monocyte activation 
respectively) were also strongly related with 
the VACS index calculated in patients on cART 
(Justice et al., 2012). The VACS index (Tate et 
al., 2013) is a combined prognostic score for 
predicting the survival of HIV-infected pa-
tients, based on CD4 cell count, HIV-RNA, 
HBV, HCV status, estimated glomerular fil-
tration rate (eGFR) and FIB-4 (platelets, ALT, 
AST, Age). It also incorporates multifaceted 
HIV effects, multimorbidity, and toxicity. Al-
though VACS does not include inflammatory 
markers, it is considered a reliable proxy of 
inflammatory status and is currently used in 
several studies. 
Recent evidence supports a role of asymmetric 
dimethylarginine (ADMA) as a valuable predic-
tor of vascular events. ADMA is an endogenous 
inhibitor of endothelial nitric oxide (NO) syn-
thase, an endogenous anti-atherogenic mole-
cule. Any condition that will reduce endothelial 
NO production may therefore promote athero-
sclerosis. In the general population, ADMA 
levels were reported to predict cardiovascular 
events and mortality (Boger 2003).
Studies in HIV-infected patients showed that 
elevated levels of ADMA are associated with 
low CD4 count and high viral load (Baker et al., 
2012; Parikh et al., 2013). Moreover, ART initi-
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ation leads to a decline in ADMA levels, which 
are also related to the degree of inflammation 
and coagulation parameters. This finding sug-
gests a role of ADMA upregulation in contrib-
uting to premature vascular disease in HIV-in-
fected individuals.
The role of ART and the reduction of HIV rep-
lication in the containment of the inflamma-
tory response are also proved by the reduction 
of the serum level of several other surrogate 
markers of inflammation. On the other hand, 
some of these biomarkers do not seem to be 
significantly influenced by a short-term treat-
ment. This happened, for example, in a lon-
gitudinal study conducted in advanced naïve 
HIV patients, showing high base-line levels of 
ICAM-1, VCAM-1, IL-6, D-dimer and hsCRP. Af-
ter three months on ART, D-dimer levels were 
significantly decreased, while ICAM/VCAM 
were further increased and remained stable 
throughout the 12-month follow-up (Bellacosa 
et al., 2012). In a combined analysis from WIHS 
and MACS, the initiation of effective ART was 
associated with a decline in IL-6 and D-dimer, 
but an apparent increase in C-reactive protein 
(CRP) (Palella et al., 2010). These findings con-
firm the possible persistence of an ‘inflamma-
tory background’ despite the virologic success 
of ART, and suggest that in different phases of 
HIV infection there are different chances to 
limit inflammation and inflammation-related 
comorbidities by ART. 
The different behavior of the biomarkers of 
inflammation might also relate to coinfection 
with other viruses, such as HCV. In the Study 
of Fat Redistribution and Metabolic Change in 
HIV Infection (FRAM), CRP was considerably 
lower in HIV and HCV-coinfected individuals 
than in either controls or in HIV-monoinfected 
patients (Tien et al., 2010). 
In the general population, the predictive gain 
obtained adding the evaluation of inflamma-
tion biomarkers to conventional risk factors 
is still minimal (Melander et al., 2009). Never-
theless, some biomarkers are widely utilized in 
predicting cardiovascular risk. A body of evi-
dence demonstrated that high sensitivity C-re-
active protein (hsCRP) levels are an indepen-
dent predictor of future myocardial infarction 
and stroke among apparently healthy men and 
women (Ridker et al., 1997; Tracy et al., 1997; 
Koenig et al., 1999; Danesh et al., 2000; Ridker 
et al., 2000), and the addition of CRP testing to 
standard lipid screening seems to provide an 
improved method to determine vascular risk 
(Ridker et al., 1998; Ridker et al., 2000). 
In a recent study in HIV patients, high hsCRP 
was associated with cardiovascular disease 
risk, independently from traditional cardiovas-
cular risk factors. HIV replication, the type of 
ART and high IL-6 and P-selectin levels were 
also independently associated with increased 
CVD risk, although the association was weaker 
than for hsCRP (De Luca et al. 2013).
Outcome. In conclusion, HIV-infection is re-
sponsible of persistent inflammation which can 
also continue in ART-treated patients with sta-
ble viral suppression. 
Chronic inflammation, in turn, is a major cause 
of non-AIDS comorbidities and aging process-
es. The use of inflammatory biomarkers in clin-
ical practice could open future perspectives to 
predict, and to prevent, the risk of non-HIV-re-
lated comorbidities, especially cardiovascular 
events. 
However, further studies are warranted to bet-
ter clarify their role in the different phases of 
HIV disease, and their gains over conventional 
risk factors in predicting the risk of develop-
ment of non-HIV-related comorbidities.
Patients with renal damage. 
Safety endpoints
P. Bonfanti
Evidence. Renal function abnormalities are 
present in a large percentage of the HIV-infect-
ed population. Patients with HIV infection may 
develop renal damage associated with HIV in-
fection itself. The risk is increased in patients 
with coinfections of HCV or HBV, diabetes, or 
hypertension (Ross 2014). The widespread em-
ployment of highly active antiretroviral therapy 
has reduced the prevalence of HIV-associated 
nephropathy and the evolution towards end-
stage renal disease. Despite this protective ef-
fect on the kidney, some antiretrovirals have 
been associated with renal toxicity, particularly 
tenofovir and less prevalently the protease in-
hibitors (Calza 2012; Ross 2014; Yombi et al., 
2014).
Conflicting data on the renal safety of tenofo-
vir are reported in the literature. Few tenofo-
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vir discontinuations due to renal toxicity have 
been reported in large clinical trials. On the 
other hand, cohort studies have shown a higher 
incidence of nephrotoxicity in patients receiv-
ing tenofovir, especially when coadministered 
with boosted protease inhibitors (PIs). Drug 
accumulation within proximal renal tubules, 
leading to mitochondrial damage, is the main 
mechanism by which tenofovir causes renal 
toxicity (Tourret et al., 2013). 
Some data gaps still remain, particularly on: 
- the reversibility of renal damage;
- the role of subclinical tubular dysfunction 
in predicting the subsequent development 
of chronic kidney disease in patients taking 
antiretroviral drugs;
- the correct assessment method for renal tox-
icity: since the damage caused by tenofovir 
is tubular, the glomerular filtration rate is 
not the best marker for renal damage;
- the lack of clear knowledge of the relation-
ship between polymorphisms in genes asso-
ciated with tubular transporters and clinical 
outcome.
The introduction of new antiretroviral agents 
such as cobicistat and dolutegravir that poten-
tially affect renal function means that filling 
these data gaps is a matter of urgency. 
Population. All HIV naïve patients should be 
screened to identify risk factors for developing 
renal damage before initiation of ARV treat-
ment. 
All treated patients, particularly those taking 
nephrotoxic drugs, should not only be moni-
tored with the GFR estimation but also using 
tubular damage markers. 
Intervention. In order to properly evaluate pa-
tients taking a tenofovir-containing regimen or 
new drugs (cobicistat, dolutegravir), the cor-
rect evaluation of proximal tubular nephropa-
thy needs to be identified and standardized. We 
need to know which markers to use, how many 
markers should be considered, and whether or 
not we should introduce new markers in clini-
cal settings. 
We also need to improve our understanding of 
the role of genetic markers associated with tu-
bular damage. 
Outcome. The prevention and identification 
of renal toxicity associated with antiretroviral 
drugs.
Patients with metabolic or bone damage. 
Safety endpoints
M. Borderi
Evidence. There is a lack of information on the 
long-term effect of cART on bone metabolism, 
and on the interactions between cART and oth-
er risk factors. Few studies have addressed the 
effect of treatment with vitamin D and PTH, 
and clinical trials do not distinguish between 
osteoporosis and osteomalacia, while data on 
vertebral fracture risk in HIV patients are still 
lacking. Published studies do not properly an-
alyze the risk of bone toxicity in women and 
men separately and in patients with different 
duration of HIV disease.
To date, we do not know what laboratory as-
sessment tests are best for screening, what oth-
er screening modalities [i.e. quantitative ultra-
sound (QUS), (Prinapori et al., 2013)] should 
be considered, how diagnostic assessments for 
bone disease should be interpreted, how fre-
quently monitoring should be performed, how 
ART should be managed in ART naïve and in 
experienced patients at risk of bone disease, 
and what ART should be selected in naïve and 
experienced patients to preserve bone mineral 
density.
Population. All HIV patients, naïve and expe-
rienced, should be screened to identify the risk 
for fragility fracture, and all patients with bone 
disease should be monitored before, following 
initiation and during ARV treatment. There 
could well be special therapeutic considerations 
in special populations (i.e. aging subjects).
Intervention. We need to identify concomitant 
risk factors and their specific role in promoting 
bone loss; to assess the risk in special popula-
tions (i.e. does cART-associated increased bone 
turnover translate into accelerated bone loss 
and rising fracture rates in postmenopausal 
women?); to better define hyperparathyroidism 
role on tenofovir-related bone loss; to have cor-
rect tools assessing osteomalacia (it would be 
useful to determine reliable markers able to dif-
ferentiate between osteoporosis and osteomala-
cia, since the treatment differs); finally, we need 
to determine the role of vitamin D deficiency 
in patients with normal PTH levels. We do not 
know which patients at risk for fragility fracture 
should be treated, at what threshold treatment 
should be initiated, what are the recommend-
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ed approaches for the treatments of patients at 
risk for fragility fracture, and if they differ in 
HIV-infected versus non-HIV-infected popula-
tions (reference to vitamin D supplementation, 
calcium supplementation, bisphosphonates).
Outcome. Final outcomes are to preserve bone 
mineral density and reduce fragility fractures.
4 - EXPERIENCED PATIENTS 
WITH RESIDUAL VIREMIA OR WITH 
LOW-LEVEL VIREMIA
Coordinator M. Andreoni
Introduction
The aim of ART is to reduce the replication of 
HIV under the limits determined for tests used 
in clinical practice (<50 HIV-RNA copies/ml). A 
favourable clinical evolution with an increase 
in CD4 lymphocytes regularly occurs in patients 
who present this result. However, low-levels of 
viral replication persist in most patients under-
going therapy. 
Two hypotheses may explain the origin of low 
viremic levels in patients undergoing antiret-
roviral treatment: residual viremia may be the 
result of a virus actively replicating because it 
is uncontrolled by the therapy currently in op-
eration or it may represent virus reactivation 
by latently infected cells. Active replication of 
the virus is confirmed by the evolution of the 
virus in some patients undergoing treatment 
in which there are new mutations and notable 
stability in the HIV-DNA levels in infected cells 
(Buzon et al., 2011). On the other hand, other 
studies have shown that intensification of the 
therapy using various pharmaceutical drugs is 
not able to change the levels of residual viremia 
demonstrating that an actively replicating virus 
is not being dealt with in these cases (Dinoso et 
al., 2009; Yukl et al., 2010b; Gandhi et al., 2012; 
Negredo et al., 2013).
It has been well known since 1995 that there is 
a rapid reduction of viremia at the start of ART. 
This reflects the short half-life of the free virus 
in the plasma and that of activated T CD4 lym-
phocytes that represent the cells that produce 
most of the virus found in the plasma. 
In fact, various studies have shown that when a 
patient starts a highly effective therapy plasma 
HIV-RNA levels are rapidly and exponentially 
reduced. However, it is important to remem-
ber that all of the antiretroviral pharmaceutical 
drugs used prevent the infection of new cells 
without blocking the production of viruses by 
cells with previously integrated virus. The rate 
of virus level reduction produced by cells in-
fected again has been measured and found to 
be similar in all patients unrelated to the stage 
of disease. This rate of reduction of new virus 
production has been used to calculate that the 
half-life of activated T CD4 lymphocytes is only 
1-2 days and that the rapid initial reduction of 
the virus in the plasma is due to the turnover 
of activated CD4, which live for approximately 
one day. 
The start of therapy in this first phase is followed 
by a second phase with a slower reduction in 
virus levels due to infected cells producing vi-
ruses with a longer half-life, the macrophages. 
In most patients, viremia in this second phase 
falls below the determinable levels (<50 copies/
ml HIV-1 RNA in plasma). Eradication of this 
cellular component needs at least 2-3 years of 
continuous highly effective therapy.
However, the opportunity to eradicate the in-
fection has been completely frustrated by the 
discovery of a third population of infected cells 
with an even longer half-life. In fact, HIV can 
infect various types of immune cells in the 
initial phase of infection such as monocytes, 
macrophages, NK cells, and T lymphocytes (es-
pecially unactivated CD4 cells) in addition to 
other non-immunising cells in which the virus 
maintains its latent form integrating with the 
cellular genome and preserving its potential to 
replicate. The cell reservoirs are stable through 
time with either no replication or a reduced 
frequency of replication. Furthermore, these 
cells would be less susceptible to the effect of 
the pharmaceutical drugs and the action of the 
immune system consequently favoring the per-
sistence of the virus.
This cell population is the actual viral reservoir. 
It is mainly composed of resting T CD4 lympho-
cytes that in normal physiology represent most 
of the T lymphocytes that may be naïve and 
consequently still not responding to extraneous 
or memory antigens and so have already par-
ticipated in an immune response. When resting 
lymphocytes meet an antigen, they are activat-
ed and divide generating cellular electricity ac-
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tivated by the same antigenic specificity. Many 
of these activated cells die at the end of the im-
mune response while others return to a resting 
state like memory cells. These cells persist for 
a long time and their decay is related to future 
immunological responses against specific anti-
gens. Therefore, HIV can infect some lympho-
cytes which, after their activation, return to 
resting state like memory cells with an integrat-
ed untranscribed viral genome. 
Consequently, should they be activated, the cell 
reservoirs produce new viral particles. The T 
memory cells with the integrated viral genome 
are verifiable even though not numerous in the 
order of one every unactivated 106-107 CD4 cell 
in both patients with acute infection and those 
with chronic and persistent infection indepen-
dent of the antiretroviral therapy. Each cell res-
ervoir preserves the virus through its potential 
to replicate itself exponentially. Furthermore, 
precisely because of their function as memory 
cells, these cells have a very long half-life of ap-
proximately 5 months, which increases in pa-
tients undergoing HAART therapy. In particular, 
a study of patients with viremia <50 copies/ml 
treated for more than 7 years calculated a half-
life for these cells of 44.2 months, evaluating 
that for one eradication of HIV from the latent 
reservoir, an effective therapy of approximately 
73 years would be necessary (Finzi et al., 1999).
The existence of this stable latent reservoir leads 
to the idea that there is a third phase of viral 
decay: a small number of latently infected cells 
are activated each day and produce virus that is 
not able to infect new cells but is released into 
the plasma at low-levels resulting in residual vi-
remia. This third phase cannot be demonstrat-
ed using the classic tests involving dosage of the 
viremia because the levels are too low and can 
either be found using highly sensitive methods 
or in the form of blips in some cases. 
Some studies have found that the reservoir 
cells producing viral particles can express small 
quantities of viral RNA and produce a limited 
number of virions and not only do this when 
activated but also when dormant (Swiggard et 
al., 2004; Pace et al., 2012). Consequently, the 
virus is cultivatable in most infected subjects 
at any stage of disease including during highly 
suppressive therapy. This phenomenon is re-
lated to the fact that the virus integrates itself 
near the genes with the greatest transcriptional 
activity. It is important to remember that none 
of the antiretroviral pharmaceutical drugs cur-
rently available or being developed is able to act 
on HIV DNA that is already integrated.
In conclusion, the presence of residual viremia 
in patients undergoing highly active therapy 
may be due to both a virus produced by latently 
infected resting cells that have been activated 
and by a virus produced by cells infected again 
in which the infection has not been controlled 
by antiretroviral therapy. In the light of this 
consideration only a reduction in the number 
of copies of HIV-DNA through the course of 
time is able to demonstrate that the therapy 
activated is not only able to control the repli-
cation of free virus in plasma but also controls 
virus released into cells.
From the clinical point of view, it is critical to 
understand that if very low-levels of replica-
tion are sufficient for new mutations of phar-
macological resistance to develop in individual 
patients, the therapy will consequently fail. It 
has been demonstrated that the viruses that 
replicate themselves at such low-levels can also 
produce clones with individual mutations of re-
sistance but these are unlikely to generate viral 
particles with multiple mutations of resistance. 
Certainly, the higher the levels of residual vire-
mia, the greater the risk of the therapy failing. 
Understanding this phenomenon justifies the 
assumption that ART should always provide for 
the use of pharmaceutical drugs for which re-
sistance only occurs in the presence of multiple 
mutations. 
Lastly, further studies should help clarify 
whether or not low-levels of virus replication 
are capable of maintaining a state of immu-
noactivation and hence inflammation both of 
which underlie chronic degenerative patholo-
gies and neoplasia frequently found in patients 
effectively treated using antiretroviral therapy.
Patients with suppressed or residual 
viremia
M.R. Capobianchi, A. Ammassari
The main goals of cART are the achievement 
of “complete virologic suppression” for as long 
as possible, together with the improvement of 
quality of life, the restoration and maintenance 
of the immune system and the prevention of 
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HIV transmission. According to current guide-
lines (European AIDS Clinical Society (EACS) 
2014; HIV/AIDS Italian Expert Panel 2014; Pan-
el on Antiretroviral Guidelines for Adults and 
Adolescents 2014b), “complete virologic sup-
pression” is achieved if plasma VL drops to lev-
els below 50 copies/ml, conventionally assumed 
as the lower limit of detection of the molecular 
tests currently available, at 6 months after start 
of cART. In clinics nowadays, the use of pow-
erful therapeutic regimens and the adoption of 
genotype-driven antiretroviral combinations 
allow “complete virologic suppression” to be 
achieved in most treated patients: around 65-
85% (Gill et al., 2010; Moore and Bartlett 2011). 
Continuing cART administration is necessari-
ly lifelong, also when “complete virologic sup-
pression” is reached and is stable for a long 
time, because the eradication of HIV infection 
cannot be achieved with currently available an-
tiretroviral regimens due to viral persistence 
(Deeks et al., 2013). In fact, in the very early 
phase of HIV infection a “pool” of latently in-
fected cells called a reservoir is established with 
a long half-life and releasing minimal amounts 
of viral particles also in the presence of effec-
tive therapy and prolonged suppression of vi-
remia. Resting memory CD4 T-lymphocytes 
represent the main component of the reservoir, 
but other cell types hosting the virus genome in 
an integrated form also contribute to HIV per-
sistence (Chun et al., 1995; Pierson et al., 2000; 
Zhu et al., 2002; Sundstrom et al., 2007; Roz-
era et al., 2009; McNamara and Collins 2011; 
Palmer et al., 2011; Watters et al., 2013; Abreu et 
al., 2014). In the absence of therapy, active viral 
replication continuously refills the reservoir. In 
the presence of cART, the amount of free virus 
in the blood falls to levels undetectable with the 
currently available diagnostic tests, but the vi-
rus persists as provirus, integrated into the ge-
nome of the cells that can survive for years in 
a resting state. When these cells receive a stim-
ulation signal, they transit to a metabolically 
active state, resulting in the production and 
release of viral particles that infect new target 
cells. Therefore, even when viremia is reduced 
to levels <50 copies/ml, minimal amounts of 
virus are always produced and released in the 
bloodstream replenishing residual viremia (RV) 
(Van Lint et al., 2013).
Two models have been suggested on the origin 
of RV during effective cART (Shen and Silicia-
no 2008). According to the first model, RV is 
the result of virus release from latently infect-
ed CD4 T-cells, stochastically activated follow-
ing specific antigenic stimulation. Under these 
conditions, RV is unable to originate new repli-
cation cycles, due to the presence of antiretrovi-
ral agents. However, recent studies have shown 
that in many patients RV is dominated by viral 
clones that are profoundly underrepresented in 
resting CD4 T cells from the peripheral blood, 
suggesting an additional source of residual vi-
remia (Brennan et al., 2009; Sahu et al., 2009). 
The other model suggests that RV is the con-
sequence of a reduced concentration of an-
tiretroviral drugs in particular compartments, 
named HIV sanctuaries (lymphoid organs, cen-
tral nervous system, genital tract, renal epithe-
lium), where the virus continues to replicate at 
low-levels and/or undergoes cell-to-cell spread. 
Several lines of evidence indicate the two mod-
els as not mutually exclusive and probably co-
exist in different proportions during time (Joos 
et al., 2008; Shen and Siliciano 2008; Sahu et 
al., 2009; Yukl et al., 2010a; Anderson et al., 
2011; Gandhi et al., 2012). 
Interestingly, several studies and clinical trials 
investigating cART intensification through ad-
dition of another antiretroviral, such as Ralte-
gravir or Maraviroc, to a virologically effective 
cART have not been able to demonstrate reduc-
tion or elimination of RV (McMahon et al., 2010; 
Hatano et al., 2011; Llibre et al., 2012; Hatano 
et al., 2013a; Puertas et al., 2014). Nevertheless, 
in some effectively treated patients a rapid and 
transient increase in the level of 2-LTR circles 
was found, indicating that cART intensification 
and optimization may impact on residual VL 
replication (Hatano et al., 2013a) and a perhaps 
limited effect on CD4 T cell reconstitution has 
been suggested (Negredo et al., 2013; Rusconi 
et al., 2013). 
Given these facts and thanks to technological 
improvements, several studies have been start-
ed, aimed at answering a new clinical question: 
should patients who have a very low, but “de-
tectable” plasma VL be considered treatment 
failures or doomed to fail? Innovative issues/
needs are challenging the scientific community, 
such as to establish a new cut-off threshold val-
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ue of VL to define therapeutic success, to inter-
pret and ascribe a precise clinical significance 
to low-levels of viral load, and to design better 
therapeutic management strategies for patients 
with low-levels of plasma VL.
Various tests have been developed to quanti-
fy RV (Amendola et al., 2011; Glaubitz et al., 
2011; van Rensburg et al., 2011; Yukl et al., 
2011; Taylor et al., 2013) and the presence of 
RV in virologically suppressed cART-treated 
individuals, even after many years, has been 
widely described (Palmisano et al., 2005; 
Palmer et al., 2008; Maggiolo et al., 2012). 
Based on published studies, approximately 
39-60% of HIV-positive cART-treated individ-
uals with viremia below 50 copies/ml have RV, 
while in 40-71% of cases plasma VL is below 
3 copies/ml(Doyle et al., 2012; Gianotti et al., 
2012; Maggiolo et al., 2012). The levels of RV 
in virologically suppressed individuals ranges 
from 1-5 to 20-30 copies/ml (average about 3 
copies/ml) and fluctuates around a set-point 
value for long time (Havlir et al., 2003; Silicia-
no et al., 2003).
The clinical significance of the RV level is cur-
rently the objective of numerous studies and 
should further be investigated, particularly 
by looking at the association with therapeu-
tic failure, such as virologic and immunologic 
outcome, and immune activation. At the same 
time, factors predictive of RV have to be de-
scribed in detail in order to allow for identifica-
tion of the most vulnerable patient population. 
In several observational studies, RV has been 
shown to increase the risk of subsequent viro-
logic rebound (i.e. >50 copies/ml, >400 copies/
ml)(Widdrington et al., 2011; Doyle et al., 2012; 
Gianotti et al., 2012; Henrich et al., 2012; Mag-
giolo et al., 2012), virologic rebound followed 
by a cART change (Doyle et al., 2012), and 
lower CD4 cell recovery (Widdrington et al., 
2011; Gianotti et al., 2012; Henrich et al., 2012). 
However, besides the impact of a low-level vi-
rologic set-point on virologic rebound, adher-
ence behavior may also play an important role. 
Although the interplay of these variables has 
not been extensively investigated, it seems rea-
sonable to affirm that patients with higher RV 
self-reporting non-adherence behaviors are the 
most vulnerable patient population with the 
highest rebound rates when compared to those 
having undetectable RV or with detectable RV 
and optimal adherence to cART.
The relationship between persistency of RV 
and immune activation as well as chronic in-
flammation is controversial and still under 
investigation. Some studies found increased 
T-cell activation (Mavigner et al., 2009) and 
higher blood levels of soluble immune ac-
tivation markers (Ostrowski et al., 2008) in 
cART-treated patients with RV when compared 
to those without. Other researchers document-
ed a correlation of plasma RV with the size 
of the CD4 T cell viral reservoir, but not with 
markers of immune activation, suggesting that 
reactivation of the latent viral reservoir may 
not be the sole source of residual plasma vire-
mia (Ostrowski et al., 2008). Notably, Hatano 
et al., found that even “elite controllers” with 
pre-cART plasma HIV RNA levels <40 copies/
ml had a statistically significant decrease in 
ultrasensitive plasma HIV RNA levels after ini-
tiation of ART together with a statistically sig-
nificant decrease in HIV antibody levels and 
a reduction in immune activation confirming 
that some HIV replication persists in control-
lers and contributes to a chronic inflammato-
ry state (Hatano et al., 2009; Chun et al., 2013; 
Hatano et al., 2013b).
With regard to factors influencing RV, baseline 
levels of viremia before starting cART (Chun 
et al., 2011), duration of virologic suppression 
(Maggiolo et al., 2012; Allavena et al., 2013), 
and deepness of HIV RNA suppression (Mag-
giolo et al., 2012) all seem important factors 
affecting the extent of RV. Female gender and 
younger age probably favor “non-detectable” 
RV (Allavena et al., 2013). Fewer previous reg-
imens (Allavena et al., 2013), non-nucleosid-
ic reverse transcriptase inhibitor based cART 
(Bonora et al., 2009; Haim-Boukobza et al., 
2011; Maggiolo et al., 2012) and composition 
of the therapeutic regimen can influence RV 
levels due to the different genetic power of an-
tiretrovirals and their ability to cooperate with 
each other (Shen et al., 2008; Bonora et al., 
2009; Haim-Boukobza et al., 2011). The levels 
of RV correlate directly with both the amount 
of circulating CD4 T-lymphocytes and with the 
proviral DNA load before the beginning of ART 
(50). Today, however, it is not yet possible to 
establish a precise relationship between these 
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two virological parameters, and in addition the 
size of the HIV reservoir is probably profound-
ly underestimated (at least 50 times) (Siliciano 
and Siliciano 2013). 
Further research is needed to address the issue 
of RV and specific clinical and virologic situa-
tions. In particular, the role of coinfection with 
hepatitis viruses as well as with CMV and EBV 
on RV levels still needs to be assessed. It is also 
possible that patients having clinical involve-
ment of HIV sanctuaries, such as the central 
nervous system, may have higher RV because 
of continuing viral replication due to lower an-
tiretroviral action in this anatomical district. 
Moreover, the time needed to obtain low-levels 
of RV (i.e. <3 cp/ml) is currently under investi-
gation and may be substantially different from 
the 6 months suggested by HIV guidelines for 
achieving treatment success (HIV RNA <50 
cp/ml). Finally, the relationship between HIV 
RNA and HIV DNA decay curves needs to be 
explored.
In conclusion, the significance of RV is at pres-
ent one of the most interesting research topics 
in the field of HIV for developing new thera-
peutic strategies aimed at eradicating HIV or 
at finding a functional cure for the infection. 
In the past, maximal attention was paid to the 
power of antiretroviral regimens and the pa-
tient’s medication adherence only when viremia 
levels in plasma resulted detectable and quan-
tifiable. Now, with more sophisticated tools to 
detect and measure HIV viremia, therapeutic 
interventions to attack the virus directly in the 
reservoir may need to include RV as a marker 
of incomplete viral suppression.
Patients with low-level viremia
M. Clementi, S. Rusconi
Evidence. Evidence confirming the importance 
of suppressing HIV-1 viremia comes from the 
large body of work describing the immunolog-
ical response to antiretroviral therapy. Indeed, 
therapy for antiretroviral naïve HIV-1-infected 
subjects may differ from that for drug-experi-
enced individuals, and its kinetics, including 4 
reduction steps, are well characterized (Palm-
er et al., 2011; Doyle et al., 2012). Various HIV 
therapeutic guidelines (from DHHS to EACS, 
including national ones) state that the goal of 
antiretroviral therapy is the optimum suppres-
sion of viral replication, which is generally de-
fined as a viral load persistently below the level 
of detection (<20-75 copies/ml), which depends 
on the assay used. From this point of view, it 
is important to emphasize the elusiveness of 
the definition of “low viremia level” since it has 
been used with various nuances both in and 
outside clinical trials, with HIV-RNA cut-offs 
ranging from 1 to 400 copies/ml (Doyle and Ge-
retti 2012; Doyle et al., 2012).
The goal in the therapeutic armamentarium of 
reaching a persistent viral suppression in the 
peripheral plasma is balanced by the concept 
that a significant drop in HIV-1 burden will also 
occur in reservoirs, either tissutal or cellular. 
Different drug classes can act in different ways 
and some, namely integrase inhibitors (INI) 
and also ritonavir-boosted protease inhibitors 
(PI/r), can cause a rapid drop in HIV-1-RNA 
particularly in the first phase of viral decay 
(Murray et al., 2007). 
Nevertheless, sensitivity tests confirmed the 
persistence of HIV-1-RNA load in approximate-
ly 80% of subjects who received a suppressive 
HAART for more than 7 years. Interruption of 
antiretroviral treatment results in a dramatic 
rise of viral replication, which derives from a vi-
ral replication that is not completely controlled. 
Reduced adherence, even during a successful 
antiretroviral regimen, can inexorably lead to 
sustained ongoing viral replication consequent-
ly leading to the emergence of drug resistance 
and to virological failure.
During early antiretroviral treatment, a vire-
mia decline of <1 log at week 4 is significantly 
correlated with an increased risk of virological 
failure. Low-level viremia may persist despite 
long-term virological success. This is due to 
the continuous production of viral particles by 
HIV-1-infected cellular reservoirs. The clini-
cal consequences of this residual viremia can 
be dangerous for the clinical progression of 
HIV-infected patients (Dornadula et al., 2001).
Where does this low-level HIV-1 replication 
originate? There are several sources for this 
increasingly controlled viral burden, including 
maintenance of a transcriptionally silent (la-
tent) HIV-1 genome in long-lived, resting target 
cells such as CD4 memory T cells, proliferation 
of the latently infected cells, inadequate an-
ti-HIV-1 clearance mechanisms, and ongoing 
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de novo infection of susceptible target cells 
through continued viral replication. 
Analysis of HIV-1-RNA results in preceding 
years can predict the persistence of detectable 
levels of plasma viremia. A recent study has 
demonstrated that there is a significant differ-
ence in the virologic outcome in three levels 
of plasma viremia:, always under 1 copy/ml, 
between 1 and 50 copies/ml, and never fully 
suppressed. So it is clear that control of virus 
replication is a dynamic process and that the 
present virus comes from one that was previ-
ously uncontrolled.
Population. The analysis of low-level viremia 
is definitely important for HIV-1-infected sub-
jects in different clinical and therapeutic set-
tings. This analysis needs to be carried out to 
compare significant differences between base-
line and further time-points.
The conditions that may be considered include 
acute infection, chronic infection, and in the 
case of virologic success, therapeutic strategy 
of induction-maintenance, PI/r monotherapy 
and salvage therapy.
PI/r monotherapy is particularly interesting in 
the light of more recent PI/r. Two clinical tri-
als using darunavir (DRV)/r have been report-
ed: MONET and MONOI. Analysis of HIV-1 
RNA <5 copies/ml at week 144 in the MONET 
study (observed data analysis) found 83.3% 
and 80.4% in the standard and DRV/r therapy 
arms respectively The proportion of subjects 
enrolled with HIV-1 RNA <1 copy/ml at week 
144 in the MONET study was 66% and 63% in 
the triple and monotherapy arms respectively 
(Lambert-Niclot et al., 2011).
There an increasing patient population receiv-
ing different anti-HIV-1 compounds belonging 
to the class of integrase inhibitors (INI).
At the time of writing, Raltegravir (RAL) is the 
only INI that is fully licensed by both the FDA 
and EMA. This compound has been studied in 
several clinical trials including BENCHMRK 
trials (Steigbigel et al., 2010) in drug-experi-
enced subjects with virological failure. Due to 
the excellent safety profile and potency of RAL, 
its use has been extended (July 2009) to drug-
naïve individuals - e.g. STARTMRK trial (Len-
nox et al., 2010).
Several trials of Elvitegravir (EVG) have been 
completed but it is still early in its clinical use. 
The drug is licensed in the United States in a 
single tablet regimen (Stribild) and has received 
a favorable opinion from the EMA.
dolutegravir (DTG) is the newest INI, which has 
had very convincing results. DTG was tested in 
INI-failing patients in the Viking-3 trial (Nich-
ols et al., 2013), in drug-naïve subjects as in the 
Spring-2 & Single trials (Curtis et al., 2013), and 
more recently in drug-experienced INI-naïve pa-
tients in the Sailing trial (Cahn et al., 2013).
Intervention. Several laboratory parameters 
such as inflammatory biomarkers and indica-
tors of immune-activation can be investigated: 
hsPCR, IL-6, D-dimer, CD38+DR+, CD14/LPS, 
and annexin-V. HIV-1 DNA quantification. Al-
though HIV-1 DNA quantification in PBMCs 
and other cell sources has been reported, quan-
tification of the various forms of HIV-1 DNA 
within cells currently remains a research goal. 
The various forms of HIV-1 DNA include inte-
grated HIV-1 DNA, linear unintegrated HIV-1 
DNA, and 1 or 2-LTR circles. HIV-1 DNA forms 
that can be quantified include total HIV-1 DNA, 
2-LTR circles, and integrated HIV-1 DNA, al-
though methods for the latter DNA form are 
still being optimized.
Outcome. Low-level viremia is caused by the 
continuous production of viral particles in 
HIV-1-infected cellular reservoirs despite an-
ti-retroviral therapy. This condition reflects an 
incomplete block of viral replication by treat-
ment and exposes the patient to the selection 
of multi-drug-resistant viral variants. From 
this point of view, low-level viremia can be 
considered an at-risk condition, and the clini-
cal consequences of this residual viremia can 
be dangerous for the clinical progression of 
HIV-1-infected patients (Dornadula et al., 2001).
CONCLUSION
Evolution of HIV clinical practice is strictly de-
pendent on the development of new approach-
es able to fill the present gap between scientific 
evidence and real life environment. In recent 
years, levels of awareness on the possible issues 
affecting clinical trials due to incorrect defini-
tion, duration of observation and patient en-
rollment have been raised. This position paper 
identifies critical parameters and population 
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characteristics that need to be taken in account 
for the design of future clinical studies. New 
and more accurate methodologies and outcome 
measurements of efficacy and safety will play a 
fundamental role in addressing these questions. 
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